MP Materials Corp. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. MP Materials operates Mountain Pass, a rare earth mine and processing facility, and is developing downstream separation, metal, alloy and magnet manufacturing capabilities.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $52.5 million | $124.4 million | $212.2 million | $434.3 million |
| Operating income (loss) | $(17.5) million | $79.2 million | $15.9 million | $289.9 million |
| Net income (loss) | $(4.3) million | $63.2 million | $40.6 million | $222.0 million |
| Diluted EPS | $(0.02) | $0.33 | $0.22 | $1.16 |
| Adjusted EBITDA (non-GAAP) | $15.6 million | $91.4 million | $101.2 million | $333.6 million |
- Revenue and pricing: Q3 revenue fell 58% year over year, primarily as realized price per REO metric ton fell 51% to $5,718 and REO sales volume declined 14% to 9,177 metric tons. For the nine-month period, revenue declined 51%; realized price was down 46% and sales volume down 8%.
- Margins and costs: Q3 operating margin was approximately negative 33%, compared with approximately positive 64% a year earlier. Cost of sales, excluding depreciation, depletion and amortization, was broadly flat in Q3 at $22.2 million. Production cost per REO metric ton rose 22% to $2,020; the nine-month figure rose 19% to $1,977.
- Cash flow and investment: Nine-month operating cash flow was $76.5 million, versus $314.4 million. Property, plant and equipment additions were $188.9 million; reported free cash flow (non-GAAP) was negative $111.4 million.
- Liquidity and debt: Cash, cash equivalents and short-term investments totaled $1.085 billion at September 30, compared with $1.182 billion at year-end 2022. Convertible notes had $690 million principal outstanding, due April 2026; net carrying value was $681.1 million. Equipment notes totaled $5.3 million.
- Other income: Q3 other income was $14.5 million, largely reflecting interest and investment income; nine-month other income was $42.0 million. It materially offset operating weakness.
Material changes versus prior periods
- The lower rare earth concentrate revenue reflected a substantially softer rare earth pricing environment and lower sales volumes. Management attributed lower volumes in part to retaining feedstock for Stage II separation rather than selling it as concentrate.
- Operating costs increased as new Stage II facilities entered service: nine-month depreciation, depletion and amortization rose to $37.1 million from $12.8 million, while advanced projects, start-up, development and other expense increased to $25.7 million from $6.2 million.
- Stage II commissioning began yielding separated products: the company produced 50 metric tons of NdPr in Q3, but reported no NdPr sales for the quarter.
- Capital spending and development continue to shift the business beyond concentrate production. Property, plant and equipment, net, rose to $1.098 billion from $935.7 million at year-end 2022.
Outlook, commentary and risks
- Management anticipated beginning sales of separated products to U.S. and global customers in Q4 2023, including Japanese customers through Sumitomo. It cautioned that reaching designed Stage II throughput could take several quarters and expected per-unit NdPr costs to improve as volumes ramp.
- The GM supply agreement is expected to ramp gradually beginning in late 2023. The company is constructing its Fort Worth facility and advancing a heavy rare earth element facility at Mountain Pass.
- Management expected up to approximately $270 million of capital costs in 2023, including project completion, early HREE facility costs, Fort Worth construction and other growth and infrastructure investments. Further HREE and Fort Worth spending was expected in 2024. Project costs and schedules could increase.
- Management said existing cash and operating cash flows should meet foreseeable liquidity needs, but noted that downstream expansion will increase working-capital and capital requirements and additional financing may be needed if resources prove inadequate.
- Key risks include volatile rare earth prices and demand, reliance on Shenghe—which accounted for more than 90% of revenue—exposure to China-related market, currency and trade conditions, execution and cost risks for Stage II and Stage III, and operational, logistics, regulatory, environmental and supply-chain risks. The company reported no material changes to its previously disclosed risk factors.
- No material litigation was reported. Management concluded disclosure controls were effective as of September 30, 2023, and reported no material changes to internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether Stage II reaches designed throughput, converts production into NdPr sales, and achieves expected unit-cost improvements.
- Whether separated-product customer arrangements, including Sumitomo distribution and the GM supply agreement, translate into sales and a timely production ramp.
- Actual capital spending, project timing and remaining funding needs for the HREE and Fort Worth facilities versus management’s estimates.
- How rare earth pricing and sales volumes evolve, and the implications of continued dependence on Shenghe and China-linked refining markets.
- Cash generation excluding investment income and the company’s ability to fund growth while reported nine-month free cash flow was negative.